Ana Chelikikj
Ana Chelikikj has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Elena Grueva
University Clinic of Cardiology - Skopje
2 shared publications - Elma Kandic
University Clinic of Cardiology - Skopje
2 shared publications Silvana Jovanova
University Clinic of Cardiology, Skopje, Republic of North Macedonia
2 shared publicationsValentina Andova
University Clinic of Cardiology, Skopje, Republic of North Macedonia
2 shared publicationsZhan Zimbakov
University Clinic of Cardiology, Skopje, Republic of North Macedonia
2 shared publicationsAleksandra Georgieva
University Clinic of Cardiology, Skopje, Republic of North Macedonia
1 shared publication
Latest Publications
- 1 April 2025
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 20 (3-4) , 76-83
Capecitabine-induced Cardiotoxicity Complicated with Acute Coronary Syndrome and Acute Heart Failure: A Case Report and Review of Scientific Data
- 1 April 2025
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 20 (3-4) , 76-83
Capecitabine-induced Cardiotoxicity Complicated with Acute Coronary Syndrome and Acute Heart Failure: A Case Report and Review of Scientific Data
- Open Access
- 29 April 2023
- Published by Turkish Journal of Internal Medicine in Turkish Journal of Internal Medicine
- Vol. 5 (2) , 141-144
Acute arterial thrombosis in anticoagulated patient for acute pulmonary thromboembolism
Acute limb ischemia is rare in patients with venous thromboembolism who already receive anticoagulation treatment. Inflammation is a risk factor for thrombus formation. Patients with active ulcerative colitis, especially at the time of exacerbation, are more prone to thromboembolism, both venous and arterial. The risk for thrombosis is 18% higher, with a higher risk of bleeding. To date, there is no contraindication to any anticoagulant drug in patients with ulcerative colitis. We represent a case of a 73 year - old woman with ulcerative colitis exacerbation, hospitalized initially for pulmonary thromboembolism, that developed acute arterial thrombosis when switched on a novel oral anticoagulant.
- 29 April 2023
- Published by Turkish Journal of Internal Medicine in Turkish Journal of Internal Medicine
- Vol. 5 (2) , 141-144
Open AccessAcute arterial thrombosis in anticoagulated patient for acute pulmonary thromboembolism
Acute limb ischemia is rare in patients with venous thromboembolism who already receive anticoagulation treatment. Inflammation is a risk factor for thrombus formation. Patients with active ulcerative colitis, especially at the time of exacerbation, are more prone to thromboembolism, both venous and arterial. The risk for thrombosis is 18% higher, with a higher risk of bleeding. To date, there is no contraindication to any anticoagulant drug in patients with ulcerative colitis. We represent a case of a 73 year - old woman with ulcerative colitis exacerbation, hospitalized initially for pulmonary thromboembolism, that developed acute arterial thrombosis when switched on a novel oral anticoagulant.
- Open Access
- 23 November 2022
- Published by Scientific Foundation Spiroski (publications) in South East European Journal of Cardiology
- Vol. 3 (1) , 11-14
Acute Myocarditis after Pfizer-BioNTech COVID-19 m-RNA Vaccination
BACKGROUND: Prosthetic mechanical valve endocarditis (PVE) can be manifested as early PVE (acquired perioperatively) and late PVE (resulting from infections unrelated to the valve operation). Causes of both are similar but are late PVE are more prone to less virulent microbes. PVE resulting with paravalvular abscess is confirmed through echocardiography (transthoracic or transesophageal), it results with a high mortality rate especially if it is not early recognized. CASE PRESENTATION: We are presenting a patient with heart failure symptoms caused by PVE after Pfizer-BioNTech coronavirus disease-2019 (COVID-19) m-RNA vaccination. CONCLUSION: The exact mechanism of myocarditis in young men who received the second dose of mRNA COVID-19 vaccine is not yet known. However, this is a rare complication and most people generally recover quickly requiring only supportive treatment. In contrast, the risk of developing myocarditis from the viral infection is much higher.
- 23 November 2022
- Published by Scientific Foundation Spiroski (publications) in South East European Journal of Cardiology
- Vol. 3 (1) , 11-14
Open AccessAcute Myocarditis after Pfizer-BioNTech COVID-19 m-RNA Vaccination
BACKGROUND: Prosthetic mechanical valve endocarditis (PVE) can be manifested as early PVE (acquired perioperatively) and late PVE (resulting from infections unrelated to the valve operation). Causes of both are similar but are late PVE are more prone to less virulent microbes. PVE resulting with paravalvular abscess is confirmed through echocardiography (transthoracic or transesophageal), it results with a high mortality rate especially if it is not early recognized. CASE PRESENTATION: We are presenting a patient with heart failure symptoms caused by PVE after Pfizer-BioNTech coronavirus disease-2019 (COVID-19) m-RNA vaccination. CONCLUSION: The exact mechanism of myocarditis in young men who received the second dose of mRNA COVID-19 vaccine is not yet known. However, this is a rare complication and most people generally recover quickly requiring only supportive treatment. In contrast, the risk of developing myocarditis from the viral infection is much higher.
- Open Access
- 20 November 2022
- Published by Scientific Foundation Spiroski (publications) in South East European Journal of Cardiology
- Vol. 3 (1) , 15-17
Papillary Muscle Rupture as a Complication of Barlow’s Disease
INTRODUCTION: Mitral regurgitation (MR) is the second most common valvulopathy worldwide, which can be divided into primary and secondary. According to Carpentier’s classification, the primary MR is further divided into three types. Type II, which includes Barlow’s disease, is described as excessive mobility of the mitral valve (MV) leaflets. Morbus Barlow is a common form of degenerative disease, with an incidence of 2–3% of the general population. Echocardiography plays an important role in its diagnosis. It is a usually benign condition, with only a few severe complications. CASE REPORT: A 75-year-old male with a history of MR, for more than 10 years. On admission, the patient presented with severe fatigue and dyspnea with signs of heart failure and pleural effusion. On auscultation, a systolic murmur was noted, on all the precordium. The ECG revealed sinus rhythm with HR of 71/min and intermittent ventricular extrasystoles. An immediate transthoracic echocardiography (TTE) was performed showing myxomatous degeneration of both MV leaflets and a prolapse of the posterior leaflet. A severe MR was detected with a presumption of papillary muscle rupture (PMR). It also revealed enlarged left atrium and ventricle (LVEDd - 67 mm and LA - 46 mm), with preserved systolic function (EF~54%) and tricuspid regurgitation accompanied by pulmonary hypertension. The laboratory analyses were within normal ranges. The patient was transferred to a cardiovascular surgery clinic, where an immediate MV repair was performed. CONCLUSION: Barlow’s disease is a common echocardiography finding. Although a benign condition, it can rarely present with serious complications such as PMR, ventricular arrhythmias, and even sudden cardiac death. Echocardiography is the first imaging used for the detection of Barlow’s disease and other MV diseases. Early recognition and confirmation with TTE or transesophageal echocardiography, plays also an appropriate treatment, play a key role in patient survival and overall prognosis.
- 20 November 2022
- Published by Scientific Foundation Spiroski (publications) in South East European Journal of Cardiology
- Vol. 3 (1) , 15-17
Open AccessPapillary Muscle Rupture as a Complication of Barlow’s Disease
INTRODUCTION: Mitral regurgitation (MR) is the second most common valvulopathy worldwide, which can be divided into primary and secondary. According to Carpentier’s classification, the primary MR is further divided into three types. Type II, which includes Barlow’s disease, is described as excessive mobility of the mitral valve (MV) leaflets. Morbus Barlow is a common form of degenerative disease, with an incidence of 2–3% of the general population. Echocardiography plays an important role in its diagnosis. It is a usually benign condition, with only a few severe complications. CASE REPORT: A 75-year-old male with a history of MR, for more than 10 years. On admission, the patient presented with severe fatigue and dyspnea with signs of heart failure and pleural effusion. On auscultation, a systolic murmur was noted, on all the precordium. The ECG revealed sinus rhythm with HR of 71/min and intermittent ventricular extrasystoles. An immediate transthoracic echocardiography (TTE) was performed showing myxomatous degeneration of both MV leaflets and a prolapse of the posterior leaflet. A severe MR was detected with a presumption of papillary muscle rupture (PMR). It also revealed enlarged left atrium and ventricle (LVEDd - 67 mm and LA - 46 mm), with preserved systolic function (EF~54%) and tricuspid regurgitation accompanied by pulmonary hypertension. The laboratory analyses were within normal ranges. The patient was transferred to a cardiovascular surgery clinic, where an immediate MV repair was performed. CONCLUSION: Barlow’s disease is a common echocardiography finding. Although a benign condition, it can rarely present with serious complications such as PMR, ventricular arrhythmias, and even sudden cardiac death. Echocardiography is the first imaging used for the detection of Barlow’s disease and other MV diseases. Early recognition and confirmation with TTE or transesophageal echocardiography, plays also an appropriate treatment, play a key role in patient survival and overall prognosis.
- Open Access
- 21 October 2022
- Published by Scientific Foundation Spiroski (publications) in South East European Journal of Cardiology
- Vol. 3 (1) , 19-21
Peripartum Cardiomyopathy Due to Gestational Hypertension and Tocolytic Therapy
BACKGROUND: Peripartum cardiomyopathy (PPCM) is a rare and sometimes fatal systolic heart failure that affects women during late pregnancy or the early postpartum period. The risk factors contributing to this condition are advanced maternal age, multiparity, administration of tocolytic agents, underlying cardiac disease, iatrogenic volume overload, preeclampsia, and hypertension. In patients with gestational hypertension (GH) and other risk factors, close monitoring is mandatory during pregnancy as well as in the postpartum period. CASE REPORT: A 38-year-old patient previously treated for endometriosis, infertility, and GH was transferred from the clinic of gynecology due to diagnosed congestive heart failure. 5 days before admission, she gave birth to her first child. Before delivery, she was treated with tocolytic therapy. She received methyldopa due to GH which was abruptly discontinued after her delivery. Echocardiography on admission revealed moderately reduced left ventricular (LV) systolic function with an ejection fraction (EF) of 37% with dilated left ventricle (LV) and pulmonary artery hypertension secondary to LV failure. During hospitalization, the patient was with signs of volume overload, but with a good response on parenteral diuretic therapy. She was additionally treated with guideline-recommended heart failure therapy. The controlled echocardiography showed improvement of LV function with an EF of 42%. CONCLUSION: PPCM is a rare condition with high morbidity and mortality. An LVEF 6.0 cm, and RV involvement are associated with adverse outcomes. Although delivery of the fetus and the placenta triggers the resolution of symptoms and recovery to the nonpregnant state of various organisms, the contrary happens with blood pressure. Its peak time is 3–6 days after delivery. Hypertension medication must not be immediately terminated. Prolonged tocolytic therapy is a risk factor for PPCM due to causing decreased baroreflex sensitivity. Patients with risk factors should be closely monitored for eventual cardiac complications.
- 21 October 2022
- Published by Scientific Foundation Spiroski (publications) in South East European Journal of Cardiology
- Vol. 3 (1) , 19-21
Open AccessPeripartum Cardiomyopathy Due to Gestational Hypertension and Tocolytic Therapy
BACKGROUND: Peripartum cardiomyopathy (PPCM) is a rare and sometimes fatal systolic heart failure that affects women during late pregnancy or the early postpartum period. The risk factors contributing to this condition are advanced maternal age, multiparity, administration of tocolytic agents, underlying cardiac disease, iatrogenic volume overload, preeclampsia, and hypertension. In patients with gestational hypertension (GH) and other risk factors, close monitoring is mandatory during pregnancy as well as in the postpartum period. CASE REPORT: A 38-year-old patient previously treated for endometriosis, infertility, and GH was transferred from the clinic of gynecology due to diagnosed congestive heart failure. 5 days before admission, she gave birth to her first child. Before delivery, she was treated with tocolytic therapy. She received methyldopa due to GH which was abruptly discontinued after her delivery. Echocardiography on admission revealed moderately reduced left ventricular (LV) systolic function with an ejection fraction (EF) of 37% with dilated left ventricle (LV) and pulmonary artery hypertension secondary to LV failure. During hospitalization, the patient was with signs of volume overload, but with a good response on parenteral diuretic therapy. She was additionally treated with guideline-recommended heart failure therapy. The controlled echocardiography showed improvement of LV function with an EF of 42%. CONCLUSION: PPCM is a rare condition with high morbidity and mortality. An LVEF 6.0 cm, and RV involvement are associated with adverse outcomes. Although delivery of the fetus and the placenta triggers the resolution of symptoms and recovery to the nonpregnant state of various organisms, the contrary happens with blood pressure. Its peak time is 3–6 days after delivery. Hypertension medication must not be immediately terminated. Prolonged tocolytic therapy is a risk factor for PPCM due to causing decreased baroreflex sensitivity. Patients with risk factors should be closely monitored for eventual cardiac complications.